Center for Atherothrombotic Research in Tromsø (CART), Department of Medicine, Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway.
J Thromb Haemost. 2011 Apr;9(4):638-44. doi: 10.1111/j.1538-7836.2011.04222.x.
Osteoprotegerin (OPG) concentration in serum is associated with the presence and severity of atherosclerosis.
To investigate the association between serum osteoprotegerin and the risk of a future myocardial infarction, ischemic stroke and mortality in a general population.
PATIENTS/METHODS: OPG was measured in serum collected from 6265 subjects recruited from a general population without a prior myocardial infarction and ischemic stroke (the Tromsø Study). Incident myocardial infarction, ischemic stroke and mortality were registered during follow-up. Cox regression models were used to estimate crude and adjusted hazard ratios and 95% confidence intervals (HR; 95% CI).
There were 575 myocardial infarctions, 284 ischemic strokes and 824 deaths (146 deaths as a result of ischemic heart disease, 78 deaths because of stroke and 600 deaths due to other causes) in the cohort during a median of 10.6 years of follow-up. Serum OPG (per SD [1.13 ng mL(-1)] increase in OPG) was associated with an increased risk of a myocardial infarction (1.20; 1.11-1.31), ischemic stroke (1.32; 1.18-1.47), total mortality (1.34; 1.26-1.42), death because of ischemic heart disease, (1.35; 1.18-1.54), stroke (1.44; 1.19-1.75) and non-vascular causes (1.31; 1.22-1.41) after adjustment for age, gender, current smoking, systolic blood pressure, body mass index, high density lipoprotein cholesterol, total cholesterol, creatinine, high sensitivity C-reactive protein (CRP) and diabetes mellitus or HbA1c > 6.1%. No association was detected between OPG and incident hemorrhagic stroke (1.02; 0.73-1.43).
Serum OPG was associated with future risk of myocardial infarction, ischemic stroke, total mortality, mortality of ischemic heart disease, stroke and of non-vascular causes independent of traditional cardiovascular risk factors.
血清骨保护素（OPG）浓度与动脉粥样硬化的存在和严重程度有关。
在一般人群中，研究血清骨保护素与未来心肌梗死、缺血性卒中和死亡率之间的关系。
患者/方法：在没有先前心肌梗死和缺血性卒中的一般人群中，从 6265 名受试者中采集血清，测量 OPG（特罗姆瑟研究）。在随访期间登记了心肌梗死、缺血性卒中和死亡率的发生情况。使用 Cox 回归模型来估计粗风险比和 95%置信区间（HR；95%CI）。
在队列中，中位随访 10.6 年期间，发生了 575 例心肌梗死、284 例缺血性卒中和 824 例死亡（146 例死亡是由于缺血性心脏病，78 例死亡是由于卒中，600 例死亡是由于其他原因）。血清 OPG（每 SD[1.13ng/mL]增加 OPG）与心肌梗死（1.20；1.11-1.31）、缺血性卒中（1.32；1.18-1.47）、总死亡率（1.34；1.26-1.42）、缺血性心脏病所致死亡率（1.35；1.18-1.54）、卒中所致死亡率（1.44；1.19-1.75）和非血管原因死亡率（1.31；1.22-1.41）相关，调整年龄、性别、当前吸烟状况、收缩压、体重指数、高密度脂蛋白胆固醇、总胆固醇、肌酐、高敏 C 反应蛋白（hs-CRP）和糖尿病或 HbA1c＞6.1%后。未检测到 OPG 与出血性卒中的发生之间存在关联（1.02；0.73-1.43）。
血清 OPG 与未来心肌梗死、缺血性卒中、总死亡率、缺血性心脏病死亡率、卒中死亡率和非血管原因死亡率相关，与传统心血管危险因素无关。
